Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-8807

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-8807). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl636298807)

Label (Lbl636298807)
This is a pharmaceutical product called NILD which contains 9.5 mg of Rivastigmine and is meant to be used as a Transdermal System. Each package has 30 systems and should be stored at a temperature range of 15° to 30°C. Users are advised to only use one patch at a time and not to cut it. Children should be kept away from this product. The NDC code for this product is 63629-8807-1.*
FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical Structure (Rivastigmine 01)
FDA Label Image

Figure 1 (Rivastigmine 02)

Figure 1 (Rivastigmine 02)
FDA Label Image

Figure 2 (Rivastigmine 03)

Figure 2 (Rivastigmine 03)
This text represents data on levels of the drug Rivastigmine in ng/mL for three different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) and their corresponding sample sizes (n = 19, n = 22, n = 22, respectively).*
FDA Label Image

Figure 3 (Rivastigmine 04)

Figure 3 (Rivastigmine 04)
FDA Label Image

Figure 4 (Rivastigmine 05)

Figure 4 (Rivastigmine 05)
FDA Label Image

Figure 5 (Rivastigmine 06)

Figure 5 (Rivastigmine 06)
FDA Label Image

Figure 6 (Rivastigmine 07)

Figure 6 (Rivastigmine 07)
FDA Label Image

Figure 7 (Rivastigmine 08)

Figure 7 (Rivastigmine 08)
The text appears to be a statistical analysis of a medication named Rivastigmine Transdermal System, with results indicating an improvement over 8, 16, and 24 weeks of treatment. The analysis presents LS means, STE, and statistical significance (p-values) at different time points. The medication comes in two doses - 15 cm² and 5cm².*
FDA Label Image

Figure 8 (Rivastigmine 09)

Figure 8 (Rivastigmine 09)
This is a description of a clinical trial for the Rivastigmine Transdermal System. The text provides LS means and standard errors obtained after 8, 16 and 24 weeks of treatment. The effect of the two different dosages (15 cm? and 5 cm?) is compared using statistical significance at a level of 0.05.*
FDA Label Image

Figure A (Rivastigmine 10)

Figure A (Rivastigmine 10)
FDA Label Image

Figure B (Rivastigmine 11)

Figure B (Rivastigmine 11)
This appears to be a list of body parts where a measurement or assessment can be taken, including the upper arm, side of chest, upper and lower back. However, the meaning of "LENGE," "Z," and "Lk" is not clear and may not be relevant.*
FDA Label Image

Figure C (Rivastigmine 12)

Figure C (Rivastigmine 12)
FDA Label Image

Figure D (Rivastigmine 13)

Figure D (Rivastigmine 13)
FDA Label Image

Figure E (Rivastigmine 14)

Figure E (Rivastigmine 14)
FDA Label Image

Figure F (Rivastigmine 15)

Figure F (Rivastigmine 15)
FDA Label Image

Figure G (Rivastigmine 16)

Figure G (Rivastigmine 16)
FDA Label Image

Figure H (Rivastigmine 17)

Figure H (Rivastigmine 17)
This seems to be a warning or instruction on how to dispose of a certain type of patch. It advises to fold the sticky sides together and place it in a trash or an empty pouch, which should be saved in order to keep it away from children and pets. It is not clear what the patch is specifically for or what type of patch it is.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.